Login to Your Account

Swedish Dilafor extends reach to Asia in deal with Lee’s for obstetrics drug candidate

By Cornelia Zou
Staff Writer

Wednesday, February 26, 2014

HONG KONG – Stockholm-based Dilafor AB inked a licensing agreement for its tafoxiparin, a drug designed to prevent protracted labor, with Hong Kong’s Lee’s Pharmaceutical Holdings Ltd. (HK:0950).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription